Skip to main content
PMC home page
Gut logoLink to Gut
. 1981 Aug;22(8):663–668. doi: 10.1136/gut.22.8.663

Nicotinic acid test in the diagnosis of Gilbert's syndrome: correlation with bilirubin clearance.

W Röllinghoff, G Paumgartner, R Preisig
PMCID: PMC1420060  PMID: 7286783

Abstract

A provocation test with nicotinic acid (50 mg intravenously) was performed in 13 patients with Gilbert's syndrome and seven healthy volunteers to investigate the diagnostic value of several test parameters and to correlate them with the bilirubin clearance. The maximal increment of unconjugated serum bilirubin, the retention at four hours, and the area under the bilirubin concentration time curve. (AUC) were measured. Significant differences between patients and controls were found with regard to the AUC (7.95 +/- SD, 3.29 mmol/min/l vs. 3.08 +/- 0.57; P less than 0.001), the increment of unconjugated bilirubin (24.1 +/- 7.1 mumol/l vs. 10.2 +/- 3.2; P less than 0.001) and the retention (77.7 +/- 8.9% vs. 45.8 +/- 27.4%; P less than 0.02). Of those, the AUC discriminated best between patients and controls. Five patients with Gilbert's syndrome had normal serum bilirubin concentrations (less than 17.1 mumol/l = 1 mg%) at the time of the study, but abnormal AUC and bilirubin increment. A significant correlation was found between the bilirubin clearance and the retention (r = -0.96; P less than 0.001) as well as the AUC (r = -0.82; P less than 0.05) but not with the bilirubin increment. This simple test may be used to assess the disturbance of bilirubin clearance in Gilbert's syndrome.

Full text

PDF
668

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrett V., Berk P. D., Menken M., Berlin N. I. Bilirubin turnover studies in normal and pathologic states using bilirubin-14C. Ann Intern Med. 1968 Feb;68(2):355–377. doi: 10.7326/0003-4819-68-2-355. [DOI] [PubMed] [Google Scholar]
  2. Berk P. D., Bloomer J. R., Howe R. B., Berlin N. I. Constitutional hepatic dysfunction (Gilbert's syndrome). A new definition based on kinetic studies with unconjugated radiobilirubin. Am J Med. 1970 Sep;49(3):296–305. doi: 10.1016/s0002-9343(70)80020-1. [DOI] [PubMed] [Google Scholar]
  3. Bircher J., Blankart R., Halpern A., Häcki W., Laissue J., Preisig R. Criteria for assessment of functional impairment in patients with cirrhosis of the liver. Eur J Clin Invest. 1973 Jan;3(1):72–85. doi: 10.1111/j.1365-2362.1973.tb00332.x. [DOI] [PubMed] [Google Scholar]
  4. Bircher J., Küpfer A., Gikalov I., Preisig R. Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther. 1976 Oct;20(4):484–492. doi: 10.1002/cpt1976204484. [DOI] [PubMed] [Google Scholar]
  5. Black M., Billing B. H. Hepatic bilirubin udp-glucuronyl transferase activity in liver disease and gilbert's syndrome. N Engl J Med. 1969 Jun 5;280(23):1266–1271. doi: 10.1056/NEJM196906052802303. [DOI] [PubMed] [Google Scholar]
  6. Davidson A. R., Rojas-Bueno A., Thompson R. P., Williams R. Reduced caloric intake and nicontinic acid provocation tests in the diagnosis of Gilbert's syndrome. Br Med J. 1975 May 31;2(5969):480–480. doi: 10.1136/bmj.2.5969.480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fromke V. L., Miller D. Constitutional hepatic dysfunction (CHD; Gilbert's disease); a review with special reference to a characteristic increase and prolongation of the hyperbilirubinemic response to nicotinic acid. Medicine (Baltimore) 1972 Nov;51(6):451–464. doi: 10.1097/00005792-197211000-00002. [DOI] [PubMed] [Google Scholar]
  8. GYDELL K. On the hyperbilirubinemic and hypersideremic action of nicotinic acid on normal subjects and on patients with some hematological disorders. Acta Med Scand. 1958 Sep 5;162(1):9–27. doi: 10.1111/j.0954-6820.1958.tb01749.x. [DOI] [PubMed] [Google Scholar]
  9. GYDELL K. Transient effect of nicotinic acid on bilirubin metabolism and formation of carbon monoxide. Acta Med Scand. 1960 Aug 31;167:431–441. doi: 10.1111/j.0954-6820.1960.tb03566.x. [DOI] [PubMed] [Google Scholar]
  10. Häcki W., Bircher J., Preisig R. A new look at the plasma disappearance of sulfobromophthalein (BSP): correlation with the BSP transport maximum and the hepatic plasma flow in man. J Lab Clin Med. 1976 Dec;88(6):1019–1031. [PubMed] [Google Scholar]
  11. Kutz K., Egger G., Bachofen H., Preisig R. Eine einfache Methode zur Berechnung der hepatischen Bilirubinclearance: ihre Anwendung bei Patienten mit Gilbert-syndrom. Helv Med Acta. 1974 May;37(5-6):386–387. [PubMed] [Google Scholar]
  12. MICHAUELSSON M., NOSSLIN B., SJOELIN S. PLASMA BILIRUBIN DETERMINATION IN THE NEWBORN INFANT. A METHODOLOGICAL STUDY WITH SPECIAL REFERENCE TO THE INFLUENCE OF HEMOLYSIS. Pediatrics. 1965 Jun;35:925–931. [PubMed] [Google Scholar]
  13. Ohkubo H., Musha H., Okuda K. Studies on nicotinic acid interaction with bilirubin metabolism. Dig Dis Sci. 1979 Sep;24(9):700–704. doi: 10.1007/BF01314468. [DOI] [PubMed] [Google Scholar]
  14. Powell L. W., Hemingway E., Billing B. H., Sherlock S. Idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). A study of 42 families. N Engl J Med. 1967 Nov 23;277(21):1108–1112. doi: 10.1056/NEJM196711232772102. [DOI] [PubMed] [Google Scholar]
  15. Preisig R., Williams R., Sweeting J., Bradley S. E. Changes in sulfobromophthalein transport and storage by the liver during viral hepatitis in man. Am J Med. 1966 Feb;40(2):170–183. doi: 10.1016/0002-9343(66)90097-0. [DOI] [PubMed] [Google Scholar]
  16. Tygstrup N. Determination of the hepatic elimination capacity (Lm) of galactose by single injection. Scand J Clin Lab Invest Suppl. 1966;18:118–125. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES